NCT00346827CompletedPhase 2
Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 36
Study Overview
Brief Summary
To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.
Study Design
- Study Type
- Interventional
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 85 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least one documented "off" period per day
Exclusion Criteria
- •hypersensitivity to apomorphine; participation in a clinical trial in the last 12 weeks; pregnant or lactating females
Investigators
Similar Trials
Completed
Not Applicable
Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French HospitalsParkinson DiseaseNCT03693872Rennes University Hospital43
Recruiting
Not Applicable
Parkinsonian Patients Treated With Apomorphine Pump: Observatory of Skin LesionsPatients With Parkinson's Disease Treated With Apomorphine PumpsNCT05331573University Hospital, Rouen108
Not yet recruiting
Not Applicable
Efficacy of drug therapies in post-nasal dripKCT0004740Chungbuk National University Hospital80
Completed
Phase 1
Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly and and Healthy Younger Adult ParticipantsHealthyNCT02345148Janssen Research & Development, LLC16
Completed
Phase 2
Study Examining PrEP-001 in Healthy SubjectsInfluenza A H3N2NCT03220048Hvivo66